Stockscreener 앱 받기
1.37
2.14%
-0.03
시간 외 거래:
1.37
전일 마감가:
$1.40
열려 있는:
$1.36
하루 거래량:
39,553
Relative Volume:
0.53
시가총액:
$7.98M
수익:
-
순이익/손실:
$-14.29M
주가수익비율:
-0.3434
EPS:
-3.99
순현금흐름:
$-12.27M
1주 성능:
-3.52%
1개월 성능:
-8.67%
6개월 성능:
-25.94%
1년 성능:
-65.51%
1일 변동 폭
$1.36
$1.40
1주일 범위
$1.36
$1.49
52주 변동 폭
$1.31
$5.00
Aprea Therapeutics Inc Stock (APRE) Company Profile
명칭
Aprea Therapeutics Inc
전화
215-948-4119
주소
3805 OLD EASTON ROAD, DOYLESTOWN, MA
APRE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
1.37 | 8.16M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-12-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-06-22 | 개시 | H.C. Wainwright | Neutral |
| 2020-04-21 | 개시 | Robert W. Baird | Outperform |
| 2019-10-28 | 개시 | JP Morgan | Neutral |
| 2019-10-28 | 개시 | Morgan Stanley | Equal-Weight |
| 2019-10-28 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aprea Therapeutics Inc 주식(APRE)의 최신 뉴스
Tools to assess Aprea Therapeutics Inc.’s risk profileWeekly Stock Report & High Return Trade Guides - newser.com
Is Aprea Therapeutics Inc. stock attractive for growth ETFsJuly 2025 Action & Fast Entry and Exit Trade Plans - newser.com
Will Aprea Therapeutics Inc. stock outperform value stocksJuly 2025 Catalysts & Safe Entry Momentum Stock Tips - newser.com
Is Aprea Therapeutics Inc. stock attractive after correction2025 Sector Review & Growth Oriented Trade Recommendations - newser.com
Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge - openPR.com
Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside - FinancialContent
Aprea Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Is Aprea Therapeutics Inc. stock poised for growthPortfolio Update Summary & AI Forecast for Swing Trade Picks - newser.com
Why Aprea Therapeutics Inc. stock could outperform in 2025Trade Exit Summary & Low Risk High Win Rate Picks - newser.com
Risk vs reward if holding onto Aprea Therapeutics Inc.Portfolio Risk Summary & Free Technical Pattern Based Buy Signals - newser.com
Aprea Therapeutics Reports Early Signs of Activity in APR-1051 Cancer Trial - MyChesCo
Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors - MSN
Aprea Therapeutics, Inc. (APRE) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Aprea Therapeutics, Inc.Common Stock (Nasdaq:APRE) Stock Quote | PRN_FinancialWrapper | PR Newswire - FinancialContent
How Aprea Therapeutics Inc. stock reacts to global recession fearsQuarterly Investment Review & Verified Technical Trade Signals - Fundação Cultural do Pará
Will Aprea Therapeutics Inc. stock outperform tech sector in 2025Market Performance Report & Low Drawdown Investment Ideas - fcp.pa.gov.br
Meme Stocks: How Aprea Therapeutics Inc. stock performs in weak economy2025 Earnings Surprises & Accurate Technical Buy Alerts - Fundação Cultural do Pará
Update Recap: Will Aprea Therapeutics Inc. stock deliver shareholder value2025 Earnings Surprises & Low Risk Entry Point Tips - fcp.pa.gov.br
Aprea Therapeutics Advances with Phase 1 Study of APR-1051 in Solid Tumors - TipRanks
Aprea’s WEE1 inhibitor shows disease stabilization in early trial - Investing.com
Aprea’s WEE1 inhibitor shows disease stabilization in early trial By Investing.com - Investing.com South Africa
Aprea Therapeutics Reports Promising Trial Results for APR-1051 - TipRanks
Aprea sees early activity in APR-1051 Wee1 trial - MarketScreener
Aprea Therapeutics Provides Clinical Update on ACESOT-1051 Trial - TradingView
Aprea Therapeutics Inc (APRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):